Literature DB >> 7739751

Effects of repeated injection of cyclosporin A on pentylenetetrazol-induced convulsion and cyclophilin mRNA levels in rat brain.

M Asanuma1, N Ogawa, S Nishibayashi, Y Kondo, A Mori.   

Abstract

To investigate the relationship between the immune system and convulsions in an animal model, we examined the effects of repeated administration with the immunosuppressant cyclosporin A on pentylenetetrazol (PTZ)-induced convulsions and the changes in the mRNA expression of its binding protein cyclophilin in the rat brain. The consecutive administration of cyclosporin A (5 mg/kg, s.c., 14 days) significantly aggravated the severity of convulsions induced with PTZ 75 mg/kg, i.p. Furthermore, it down-regulated the levels of cyclophilin mRNA in several brain regions and inhibited the PTZ-induced increase of hippocampal cyclophilin mRNA. Compared with the group without PTZ pretreatment or the group treated with chronic vehicle administration after the PTZ-preinjection, chronic cyclosporin A administration after the initial injection of PTZ apparently aggravated convulsions after the second PTZ injection. Interestingly, the increase in hippocampal cyclophilin mRNA observed after a single PTZ injection was not found after the second PTZ injection in the group with PTZ pretreatment. Therefore, these findings suggest that cyclosporin A administered peripherally can affect the central nervous system, and that an immune response associated with the first convulsive episode plays a key role in severity during subsequent attacks.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7739751     DOI: 10.1007/bf00995159

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  26 in total

1.  p1B15: a cDNA clone of the rat mRNA encoding cyclophilin.

Authors:  P E Danielson; S Forss-Petter; M A Brow; L Calavetta; J Douglass; R J Milner; J G Sutcliffe
Journal:  DNA       Date:  1988-05

2.  Severe central-nervous-system toxicity associated with cyclosporin.

Authors:  J H Berden; A J Hoitsma; J L Merx; A Keyser
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

3.  Interleukin-1 augments gamma-aminobutyric acidA receptor function in brain.

Authors:  L G Miller; W R Galpern; K Dunlap; C A Dinarello; T J Turner
Journal:  Mol Pharmacol       Date:  1991-02       Impact factor: 4.436

4.  Cyclophilin: distribution and variant properties in normal and neoplastic tissues.

Authors:  A J Koletsky; M W Harding; R E Handschumacher
Journal:  J Immunol       Date:  1986-08-01       Impact factor: 5.422

5.  [Auto-cholinergic synapse dysfunction in patients with generalized epileptic seizures. A preliminary report].

Authors:  Z P Qu
Journal:  Zhonghua Shen Jing Jing Shen Ke Za Zhi       Date:  1991-06

6.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

Review 7.  Determining the prognosis of childhood epilepsies by establishing immune abnormalities.

Authors:  P A Bouma
Journal:  Clin Neurol Neurosurg       Date:  1992       Impact factor: 1.876

8.  Molecular cloning and regional distribution of rat brain cyclophilin.

Authors:  R P Lad; M A Smith; D C Hilt
Journal:  Brain Res Mol Brain Res       Date:  1991-02

9.  Effects of chronic catecholamine depletions on muscarinic M1-receptor and its mRNA in rat brain.

Authors:  M Asanuma; N Ogawa; K Haba; H Hirata; A Mori
Journal:  J Neurol Sci       Date:  1992-07       Impact factor: 3.181

10.  Effect of cyclosporin A on an experimental chronic viral infection of the central nervous system.

Authors:  O Boespflug; C Godfraind; M Tardieu
Journal:  J Neuroimmunol       Date:  1989-01       Impact factor: 3.478

View more
  1 in total

1.  Enhancement of Flow-Induced AP-1 Gene Expression by Cyclosporin A Requires NFAT-Independent Signaling in Bone Cells.

Authors:  Leah E Worton; Ronald Y Kwon; Edith M Gardiner; Ted S Gross; Sundar Srinivasan
Journal:  Cell Mol Bioeng       Date:  2014-06-01       Impact factor: 2.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.